Search
forLearn
5 / 801 resultslearn Gamma linolenic acid
learn Citronellol
learn Lamium Album Flower Extract
learn epilobium angustifolium
Research
5 / 1000+ results
research In-silico screening of potential anti-androgenic and anti-estrogenic phytocompounds from Saraca asoca for polycystic ovary syndrome treatment
Procyanidin B2 and leucopelargonidin from Saraca asoca may help treat PCOS by balancing hormones.
research Antioxidant and photoprotective potential of Polypodium leucotomos
Polypodium leucotomos is a promising natural sunscreen that helps protect skin from UV damage.
research A retrospective review of hyperaesthetic leucotrichia in horses in the USA
Hyperaesthetic leucotrichia in horses causes painful, recurring skin lesions and hair color changes, especially in Arabian and American paint horses.
research LC-ESI-QTOF-MS/MS Analysis, Cytotoxic, Antiviral, Antioxidant, and Enzyme Inhibitory Properties of Four Extracts of Geranium pyrenaicum Burm. f.: A Good Gift from the Natural Treasure
Geranium pyrenaicum extracts show potential for cancer, antiviral, and enzyme inhibition treatments.
research 575 An extract of Leontopodium alpinum prolongs anagen phase in human hair follicles ex vivo
Leontopodium alpinum extract may help reduce hair shedding by keeping hair in the growth phase longer.
Community Join
5 / 1000+ resultscommunity Using WinLevi (Clascoterone) for Seborrheic Dermatitis and Acne
Winlevi (clascoterone) is discussed as a treatment for hormonal acne and seborrheic dermatitis due to its ability to block DHT and regulate sebum production. The post suggests that Winlevi could offer a novel approach for managing seborrheic dermatitis.
community EMA is re-examining Winlevi (clascoterone at lower concentration)
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
community Pelage to present PP405 Phase 2a clinical trial full results at an upcoming medical meeting - CMO Christina Weng says
Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.
community Best Treatment In The Pipeline?
New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.
community Pelage Recruiting Now for Phase 2
Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.